Marker (samples) | Adjusted risk (%) | Adjusted RD (95% CI) | Interaction contrast (95% CI) |
---|---|---|---|
Gastrointestinal Illness b | |||
– |  | −0.1% (−1.5%, 1.2%) |  |
HumM2 | |||
0–1 | 8.0 | Ref |  |
 | 8.4 | 0.4% (−1.5%, 2.3%) |  |
≥2 | 8.7 | Ref |  |
 | 8.3 | −0.3% (−2.1%, 1.4%) | −0.8% (−3.1%, 1.6%) |
HF183 | |||
0–1 | 6.6 | Ref |  |
 | 8.0 | 1.4% (−0.5%, 3.2%) |  |
≥2 | 10.0 | Ref |  |
 | 8.8 | −1.1% (−3.1%, 0.9%) | −2.5% (−5.1%, 0.2%) |
BsteriF1 | |||
0–1 | 5.3 | Ref |  |
 | 6.9 | 1.6% (−0.6%, 3.8%) |  |
≥2 | 9.9 | Ref |  |
 | 8.9 | −1.0% (−2.7%, 0.8%) | −2.6% (−5.4%, 0.2%) |
Bunif2 | |||
0–1 | 3.2 | Ref |  |
 | 6.2 | 3.1% (0.9%, 5.2%) |  |
≥2 | 9.2 | Ref |  |
 | 8.6 | −0.6% (−2.1%, 0.9%) | −3.6% (−6.2%, −1.1%) |
Diarrhea b | |||
– |  | 0.2% (−0.8%, 1.2%) |  |
HumM2 | |||
0–1 | 4.8 | Ref |  |
 | 5.6 | 0.8% (−0.6%, 2.2%) |  |
≥2 | 5.4 | Ref |  |
 | 5.4 | 0.1% (−1.2%, 1.3%) | −0.7% (−2.5%, 1.0%) |
HF183 | |||
0–1 | 4.7 | Ref |  |
 | 5.8 | 1.1% (−0.4%, 2.7%) |  |
≥2 | 5.8 | Ref |  |
 | 5.6 | −0.2% (−1.5%, 1.2%) | −1.3% (−3.3%, 0.7%) |
BsteriF1 | |||
0–1 | 3.2 | Ref |  |
 | 4.7 | 1.5% (−0.3%, 3.2%) |  |
≥2 | 6.3 | Ref |  |
 | 6.0 | −0.4% (−1.7%, 1.0%) | −1.8% (−4.0%, 0.3%) |
Bunif2 | |||
0–1 | 2.1 | Ref |  |
 | 4.6 | 2.5% (0.8%, 4.2%) |  |
≥2 | 5.8 | Ref |  |
 | 5.7 | −0.1% (−1.2%, 1.0%) | −2.6% (−4.6%, −0.6%) |
Respiratory Illness c | |||
– |  | −0.6% (−2.1%, 0.9%) |  |
HumM2 | |||
0–1 | 7.3 | Ref |  |
 | 6.5 | −0.8% (−2.6%, 1.0%) |  |
≥2 | 7.4 | Ref |  |
 | 6.8 | −0.6% (−2.7%, 1.5%) | 0.2% (−2.3%, 2.7%) |
HF183 | |||
0–1 | 7.6 | Ref |  |
 | 6.1 | −1.4% (−3.7%, 0.9%) |  |
≥2 | 7.2 | Ref |  |
 | 6.8 | −0.4% (−2.3%, 1.5%) | 1.0% (−2.0%, 3.9%) |
BsteriF1 | |||
0–1 | 5.5 | Ref |  |
 | 5.3 | −0.1% (−2.4%, 2.1%) |  |
≥2 | 8.4 | Ref |  |
 | 7.1 | −1.3% (−3.4%, 0.9%) | −1.1% (−4.2%, 2.0%) |
Bunif2 | |||
0–1 | 3.2 | Ref |  |
 | 5.2 | 2.1% (0.1%, 4.1%) |  |
≥2 | 7.8 | Ref |  |
 | 6.8 | −1.0% (−2.7%, 0.7%) | −3.1% (−5.7%, −0.4%) |